MDM2 and neoplasm: In this regard, HIPK2 is often inactivated in tumors by multiple mechanism such as gene downregulation [33,34], gene mutation [35], protein mislocalization [36] as well as by protein degradation through MDM2 [37] or hypoxia-induced factors [38], impairing the cellular response to drug and supporting tumor progression.